Related Experiment Video

Updated: Jul 20, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Eduardo Gonzalez-Ochoa1, Ana C Veneziani1, Amit M Oza1,2

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Clinical Medicine Insights. Oncology
|August 2, 2023
PubMed

Insights

Mirvetuximab soravtansine shows promise for treating platinum-resistant ovarian cancer. This antibody drug conjugate targets folate receptor alpha, offering a new therapeutic strategy for patients with poor outcomes.

Area of Science:

  • Gynecologic Oncology
  • Medical Therapeutics
  • Drug Development

Background:

  • Ovarian cancer is a leading cause of cancer death globally, with platinum-resistant disease posing significant treatment challenges.
  • Standard chemotherapy offers poor clinical outcomes for patients with platinum-resistant ovarian cancer, highlighting the need for novel therapeutic strategies.
  • Understanding drug resistance mechanisms is crucial for developing effective treatments for ovarian cancer.

Purpose of the Study:

  • To review the current evidence on mirvetuximab soravtansine for platinum-resistant ovarian cancer.
  • To summarize the clinical activity and toxicity profile of mirvetuximab soravtansine.
  • To discuss future directions for mirvetuximab soravtansine in ovarian cancer treatment.

Main Methods:

  • Review of current clinical evidence on mirvetuximab soravtansine.
  • Focus on clinical activity and toxicity data.
  • Exploration of future therapeutic strategies.

Main Results:

  • Mirvetuximab soravtansine, an antibody drug conjugate (ADC), targets folate receptor alpha (FRα).
  • It combines a monoclonal antibody against FRα with the cytotoxic agent DM4.
  • Promising clinical activity has been observed in FRα-positive ovarian cancer patients.

Conclusions:

  • Mirvetuximab soravtansine demonstrates potential as a therapeutic option for platinum-resistant ovarian cancer.
  • Its targeted approach offers a promising strategy to overcome treatment failure.
  • Further research and clinical evaluation are warranted to optimize its use in ovarian cancer management.
Keywords:
Antibody drug conjugatefolate receptormirvetuximabovarian cancerplatinum resistance

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
243
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558